Switch theme
Sign up to access all valuation multiples
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
2004
150
LTM Revenue $2.5M
LTM EBITDA -$176M
$339M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
KalVista Pharma has a last 12-month revenue (LTM) of $2.5M and a last 12-month EBITDA of -$176M.
In the most recent fiscal year, KalVista Pharma achieved revenue of n/a and an EBITDA of -$131M.
KalVista Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See KalVista Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$176M | XXX | -$131M | XXX | XXX | XXX |
| EBITDA Margin | -6925% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$177M | XXX | -$132M | XXX | XXX | XXX |
| EBIT Margin | -6965% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$172M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | -6759% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, KalVista Pharma's stock price is $12.
KalVista Pharma has current market cap of $587M, and EV of $339M.
See KalVista Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $339M | $587M | XXX | XXX | XXX | XXX | $-3.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, KalVista Pharma has market cap of $587M and EV of $339M.
KalVista Pharma's trades at n/a EV/Revenue multiple, and -2.1x EV/EBITDA.
Equity research analysts estimate KalVista Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
KalVista Pharma has a P/E ratio of -3.4x.
See valuation multiples for KalVista Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $587M | XXX | $587M | XXX | XXX | XXX |
| EV (current) | $339M | XXX | $339M | XXX | XXX | XXX |
| EV/Revenue | 133.7x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.9x | XXX | -2.1x | XXX | XXX | XXX |
| EV/EBIT | -1.9x | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | 153.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.4x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKalVista Pharma's last 12 month revenue growth is 1367%
KalVista Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
KalVista Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
KalVista Pharma's rule of X is -3508% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for KalVista Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1367% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -6925% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3508% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
KalVista Pharma acquired XXX companies to date.
Last acquisition by KalVista Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . KalVista Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was KalVista Pharma founded? | KalVista Pharma was founded in 2004. |
| Where is KalVista Pharma headquartered? | KalVista Pharma is headquartered in United States of America. |
| How many employees does KalVista Pharma have? | As of today, KalVista Pharma has 150 employees. |
| Who is the CEO of KalVista Pharma? | KalVista Pharma's CEO is Mr. Benjamin L. Palleiko. |
| Is KalVista Pharma publicy listed? | Yes, KalVista Pharma is a public company listed on NAS. |
| What is the stock symbol of KalVista Pharma? | KalVista Pharma trades under KALV ticker. |
| When did KalVista Pharma go public? | KalVista Pharma went public in 2015. |
| Who are competitors of KalVista Pharma? | Similar companies to KalVista Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of KalVista Pharma? | KalVista Pharma's current market cap is $587M |
| What is the current revenue of KalVista Pharma? | KalVista Pharma's last 12 months revenue is $2.5M. |
| What is the current revenue growth of KalVista Pharma? | KalVista Pharma revenue growth (NTM/LTM) is 1367%. |
| What is the current EV/Revenue multiple of KalVista Pharma? | Current revenue multiple of KalVista Pharma is 133.7x. |
| Is KalVista Pharma profitable? | Yes, KalVista Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of KalVista Pharma? | KalVista Pharma's last 12 months EBITDA is -$176M. |
| What is KalVista Pharma's EBITDA margin? | KalVista Pharma's last 12 months EBITDA margin is -6925%. |
| What is the current EV/EBITDA multiple of KalVista Pharma? | Current EBITDA multiple of KalVista Pharma is -1.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
